Premium
An Efficient and Specific Protection of Non‐Thermal Plasma‐Induced Live Yeast Cell Derivative (LYCD) for Cells against Plasma Damage
Author(s) -
Ma Ruonan,
Feng Hongqing,
Guo Jinsong,
Liang Yongdong,
Zhang Qian,
Tian Ying,
Zhang Jue,
Fang Jing
Publication year - 2014
Publication title -
plasma processes and polymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 74
eISSN - 1612-8869
pISSN - 1612-8850
DOI - 10.1002/ppap.201300206
Subject(s) - catalase , superoxide dismutase , reactive oxygen species , nonthermal plasma , glutathione , saccharomyces cerevisiae , plasma medicine , chemistry , yeast , antioxidant , oxidative stress , biochemistry , plasma , microbiology and biotechnology , pharmacology , biology , enzyme , atmospheric pressure plasma , physics , quantum mechanics
With the development of plasma medicine, safety issues are emerging as a serious concern. In this study, the protective effects of live yeast cell derivative (LYCD) on yeast ( Saccharomyces cerevisiae ) and mammalian cells (NIH‐3T3) subjected to plasma treatment were investigated. The anti‐oxidative properties of LYCD were assessed by analyzing three important antioxidants: superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). The results show that LYCD can efficiently protect the S. cerevisiae and NIH‐3T3 cells against plasma treatment by elevating the survival ratio from 7 to 60% and 10 to 60%, respectively, and reverse the increased intracellular reactive oxygen species production following plasma exposure. Additionally, the protection is shown to be specific when compared with UV and H 2 O 2 treatment. SOD and CAT activities as well as GSH content of LYCD increase linearly with plasma induction time. Simultaneously, the LYCD protection efficacies are increasing with longer plasma induction time, indicating that SOD, CAT, and GSH all contribute to the protective effect of LYCD. This work suggests that the non‐toxic LYCD can serve as a promising precaution agent to enhance the safety of plasma applied directly to human body in the future.